Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

With more patients shifting to new gliptins (a category of diabetes drugs) as they go off-patent, the national pharma pricing regulator has moved quickly to cap prices of two diabetes molecules Sitagliptin and Linagliptin and their combinations.
 
Around nine per cent of India’s 1.4 billion population has Type-2 diabetes, and this has crossed 11 per cent in few urban pockets. It is thus estimated that 100 million people in India have diabetes, but about half the Type-2 diabetes cases go undiagnosed.
 
Government sources reveal that the regulator is keeping a keen watch on diabetes drug prices, and also